Today: December 14, 2017, 2:07 pm
  
Business

Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)

PR-Inside.com: 2017-10-23 23:02:01

MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), is pleased to announce the opening of its Initial Public Offering (IPO or Offer) to raise A$50 million.

The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited. The IPO has been strongly supported by the Company's existing shareholders, which include both industry partners and domestic institutional investors, such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Allan Moss and Alium Capital Management. With this Offer, Telix will further strengthen its Australian and international institutional shareholder base, including the addition of Fidelity International. Fidelity International is a cornerstone investor in the IPO and will hold approximately 10% of the issued capital of the Company upon completion of the IPO.

Telix is Chaired by ex-Macquarie Bank Chairman Mr. Kevin McCann AM. The Board of Directors consists of Caledonia Investments co-founder Dr. Mark Nelson (Non-executive Director) and Mr. Oliver Buck (Non-executive Director), co-founder and member of the Supervisory Board of ITM Group, a global leader in the production of medical isotopes. Co-founder and Chief Medical Officer Dr. Andreas Kluge, and Co-Founder and CEO Christian Behrenbruch are appointed as Executive Directors.

Dr. Behrenbruch commented, "With our portfolio of highly-promising clinical programs in renal, prostate and brain (glioblastoma) cancer, Telix is uniquely positioned for global leadership in the fast-growing field of MTR. We have excellent patient data underpinning our development programs, a highly experienced clinical development team and meaningful partnerships with thought leaders in the field. This financing will enable the company to reach several major development and commercial milestones over the next 24 months."

The offer of new fully paid ordinary shares by Telix Pharmaceuticals is made under a prospectus lodged with the Australian Securities and Investments Commission (ASIC) on 16 October 2017. The Offer comprises a Retail Offer and an Institutional Offer.

Australian-resident retail investors are eligible to apply for shares under the Retail Offer via the Offer website at www.telixpharma.com/IPO.

The Offer is expected to close on or around 8 November 2017 and Telix is expected to commence trading on ASX on 15 November 2017, under the ticker "TLX". The prospectus is available to Australian-resident investors via the Telix website at www.telixpharma.com/IPO.

For further information about the IPO, please contact:

Offer Information Line : 1800 262 299 (within Australia) or +61 1800 262 299 (outside Australia) between 9:00am and 5:00pm (AEDT) Monday to Friday during the Offer Period 
 
 Corporate Contact: 

 Dr. Christian Behrenbruch
 CEO 
 Telix Pharmaceuticals Limited
 Email: chris@telixpharma.com
 Investor and Media Relations: 

 Kyahn Williamson
 Head of Investor Relations
 WE Buchan 
 Email: kwilliamson@buchanwe.com.au


For further information about Telix Pharmaceuticals Limited and the IPO, please refer to the prospectus. Potential investors should carefully consider the prospectus and investment risk factors before deciding whether to acquire shares. Please note that the offer of shares under the IPO will be made in, or accompanied by, a copy of the prospectus and anyone who wants to acquire Telix shares under the IPO will need to complete an application form that will be in or will accompany the prospectus.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Telix Pharmaceuticals Limited via Globenewswire




# 967 Words
Related Articles
More From The Author
China's Dongfeng Makes Joint Initiative with Global [..]
Dongfeng Motor Corporation recently set up its race team and named a sailboat under its Dongfeng brand to participate in [..]
Brookfield Asset Management Notice of 2017 Q3 [..]
Date:   Thursday, November 9, 2017Time:  11:00 a.m. (Eastern Time)  BROOKFIELD, News, Oct. 23, 2017 (GLOBE NEWSWIRE) -- [..]
Gazit Globe Announces Date for Q3 2017 [..]
TEL AVIV, Israel, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), a global owner developer and [..]
Deloitte and Enstoa Announce Partnership to Bring [..]
Collaboration to address rapidly growing projects and portfolio management market TORONTO, Oct. 23, 2017 (GLOBE NEWSWIRE) -- [..]
GSMA Publishes New Report on Mobile-Enabled Digital [..]
At a high-level roundtable between the Government of Ghana and mobile industry leaders today, the GSMA launched a report in [..]
 
More From Business
Cirtek Holdings Philippines Corp Holds Its First-Ever [..]
SAN FRANCISCO, CA, Dec 8, 2017 - (ACN Newswire) - All-Asia institutional equities broker Decker & Co. hosted Cirtek Holdings [..]
Business of Intellectual Property (BIP Asia) Forum [..]
Industry Experts Gather in Hong Kong to Promote IP and Innovation HONG KONG, Dec 7, 2017 - (ACN Newswire) - [..]
Select the best flower and present it [..]
You can send flowers to your friends and relatives within the city. You can also present flowers to your beloved [..]
European Tech Startup LivingPackets Launches Pilot International [..]
A game-changing international delivery startup LivingPackets has secured support of the five-star St Pancras Renaissance Hotel, [..]
Experienced Business Coaches Launch “Business Wingmen” Podcast [..]
SANTA ANA, Calif., - November 27, 2017- Two prominent Orange County business coaches announced the formation and launch of [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.